BRAF突变与甲状腺乳头状癌临床病理学特征关系研究

doi:10.3969/j.issn.1009-976X.2022.02.004

摘要/Abstract

摘要： 目的探讨BRAF基因在甲状腺乳头状癌（PTC）中的突变率,及其与临床病理学特征的关系。方法选取2018年1月至2019年12月经手术治疗的253例甲状腺乳头状癌患者作为研究对象,分析BRAF基因突变与甲状腺乳头状癌患者临床病理学特征的关系。结果 81%的PTC患者中发现有BRAF基因的突变。BRAF突变率随着年龄的增长而增加,BRAF 突变与PTC的淋巴转移以及临床分期间比较,差异有统计学意义（P<0.05）。多因素Logistic回归分析显示年龄≥45岁、高肿瘤分期、区域淋巴结转移是BRAF突变的独立影响因素（均P<0.05）。结论 BRAF基因突变与PTC淋巴结转移、临床分期相关,而且对于甲状腺肿瘤良恶性的诊断具有重要价值。

关键词: 甲状腺乳头状癌, BRAF, 突变, 临床病理性特征

Abstract: Objective To investigate the incidence of BRAF mutation and its relationships with clinicopathological characteristics in patients with PTC. Methods 253 patients with papillary thyroid carcinoma who underwent surgery in the department of thyroid and breast surgery of the First People′s Hospital of Lianyungang from January 2018 to December 2019 were selected. The relation between the mutation of BRAF and clinicopathological features of papillary thyroid carcinoma patients was analyzed. Results The BRAF mutation was present in 81% of patients （205 of 253）. The frequency of BRAF mutation increased with age. There were significant correlations between BRAF mutation and lymph node metastasis, and between BRAF mutation and the clinical stage of papillary thyroid cancer （P<0.05）. Multivariate Logistic regression analysis showed that ≥45 years older, high clinical stage and lymph node metastasis were independent factors for BRAF mutation. Conclusion The mutation of BRAF is associated with the lymph node metastasis, and clinical stage of PTC, and may have a positive predictive value for diagnosing thyroid tumors.

Key words: papillary thyroid carcinoma, BRAF, mutation, clinicopathological feature

中图分类号:

R736.1

王培顺, 李淑琴, 王岩, 汪瑞, 高希涛, 王昭昕, 周军. BRAF突变与甲状腺乳头状癌临床病理学特征关系研究[J]. 岭南现代临床外科, 2022, 22(02): 134-137.

WANG Pei-shun, LI Shu-qin, WANG Yan, WANG Rui, GAO Xi-tao, WANG Zhao-xin, ZHOU Jun. Relationship between BRAF mutation and clinicopathological characteristics in papillary thyroid carcinoma[J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 134-137.

参考文献

[1] Luster M, Aktolun C, Amendoeira I, et al.European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium[J]. Thyroid, 2019, 29(1): 7-26.
[2] Bilimoria KY, Bentrem DJ, Ko CY, et al.Extent of surgery affects survival for papillary thyroid cancer[J]. Ann Surg, 2007, 246(3): 375-384.
[3] Albinsaad LS, Kim WW, Lee YM, et al.The appropriateness of thyroid lobectomy as an initial surgery for preoperatively detected unilateral multifocal papillary carcinoma[J]. Asian J Surg, 2021, 44(8): 1050-1055.
[4] Niederer-Wüst SM, Jochum W, Förbs D, et al.Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer[J]. Surgery, 2015, 157(1): 119-125.
[5] Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J.Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review[J]. Cancers (Basel), 2020, 12(8): 2104.
[6] Tavares C, Melo M, Cameselle-Teijeiro JM, et al.Endocrine tumours: genetic predictors of thyroid cancer outcome[J]. Eur J Endocrinol, 2016, 174(4): R117-R126.
[7] Kim HJ, Park HK, Byun DW, et al.Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area[J]. Eur J Nutr, 2018, 57(2): 809-815.
[8] Kure S, Ishino K, Kudo M, et al.Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience[J]. J Int Med Res, 2019, 47(11): 5560-5572.
[9] Yan C, Huang ML, Li X, et al.Relationship between BRAFV600E and clinical features in papillary thyroid carcinoma[J]. Endocr Connect, 2019, 8(7): 988-996.
[10] Ng JY, Lu CT and Lam AK. BRAF mutation: Current and future clinical pathological applications in colorectal carcinoma[J]. Histol Histopathol, 2019, 34(5): 469-477.
[11] Kure S, Wada R, Naito Z.Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma[J]. Med Mol Morphol, 2019, 52(4): 181-186.
[12] Yang LB, Sun LY, Jiang Y, et al.The clinicopathological features of BRAF mutatedpapillary thyroid cancers in Chinese patients[J]. Int J Endocrinol, 2015, 2015: 642046.
[13] Picarsic JL, Buryk MA, Ozolek J, et al.Molecular characterization of sporadic pediatric thyroid carcinoma with the DNA/ RNA ThyroSeq v2 next-generation sequencing assay[J]. Pediatr Dev Pathol, 2016, 19(2): 115-122.
[14] Mitsutake N, Fukushima T, Matsuse M, et al.BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profifile from Chernobyl[J]. Sci Rep, 2015, 5: 16976.

[1]	冯惠仪, 吴明玮. 非小细胞肺癌EGFR罕见突变及其靶向与免疫治疗策略[J]. 岭南现代临床外科, 2021, 21(04): 482-488.
[2]	冯慰莲, 黄仁伟, 王晓艺, 严悦溶, 伍嘉韵, 陈彩霞, 黎锋, 张锦, 严励, 徐明彤. CXCL10在甲状腺乳头状癌中的表达及其与临床特征的相关性探讨[J]. 岭南现代临床外科, 2020, 20(02): 155-160.
[3]	闵耒，何劲松*. 纳米碳对甲状腺乳头状癌术后短期疗效的影响[J]. 岭南现代临床外科, 2019, 19(04): 396-399.
[4]	韩彬，王东来，李朋，朱丽璋，韦伟. 经口腔前庭入路腔镜甲状腺癌根治手术的临床体会[J]. 岭南现代临床外科, 2019, 19(03): 285-288.
[5]	刘静，陈红星，许密，吴雨茜，刘兴州，杨川，严励，任萌*. 术后引流液外泌体hsa?miR?609在甲状腺乳头状癌发生发展中的作用及其机制探讨[J]. 岭南现代临床外科, 2019, 19(02): 150-153.
[6]	韩彬，王东来，李朋，邹丽，韦伟*. 甲状腺乳头状癌术中右侧喉返神经深层淋巴结清扫的经验和体会[J]. 岭南现代临床外科, 2018, 18(04): 421-424.
[7]	王厥，欧阳能太. PPIB 蛋白在甲状腺乳头状癌中的表达及与预后的相关性[J]. 岭南现代临床外科, 2018, 18(01): 27-31.
[8]	李勇林启谋周毅. 中央区淋巴结清扫在cN0期甲状腺乳头状癌中的应用[J]. 岭南现代临床外科, 2017, 17(04): 386-390.
[9]	曹杰智赖东明伍衡褚忠华曾育杰. 在结肠癌细胞中P53突变调控 KLF5功能及表达变化的实验研究[J]. 岭南现代临床外科, 2017, 17(04): 410-414.
[10]	谭羽灿罗灿华邹岚. P300/CBP在甲状腺乳头状癌中的表达及其临床意义[J]. 岭南现代临床外科, 2017, 17(03): 290-294.
[11]	何东添关妙珠李超李伟文苏耀荣蒋文川. 亚甲蓝定位前哨淋巴结在cN0甲状腺乳头状癌的经验与技巧[J]. 岭南现代临床外科, 2017, 17(02): 201-204.
[12]	赵竞刘生. 甲状腺乳头状癌相关基因的研究进展[J]. 岭南现代临床外科, 2016, 16(06): 642-646.
[13]	叶炜芃陈燕贤王慧中李炜玉杨琼谢德荣. 奥沙利铂或伊立替康联合氟尿嘧啶在KRAS突变型的晚期结直肠癌一线化疗中的疗效比较[J]. 岭南现代临床外科, 2016, 16(05): 553-556.
[14]	洪云黄晓明冯鉴伦曹海玲曹余彦黎颂铭. 内镜颈清术与传统颈清术治疗cN0甲状腺乳头状癌的比较[J]. 岭南现代临床外科, 2014, 14(04): 387-390.
[15]	范苗静吕志强张惠忠沈溪明. 肺腺癌患者表皮生长因子受体基因突变的临床意义[J]. 岭南现代临床外科, 2011, 11(01): 41-43.